Carsten Denkert
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
von Minckwitz G, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, Simon E, Stickeler E, Potenberg J, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marme F, German Breast Group Investigators. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer 2015; 121:3639-48.
25.06.2015A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
25.06.2015Cancer 2015; 121:3639-48
von Minckwitz Gunter, Thomssen Christoph, Huober Jens, Denkert Carsten, Alfer Joachim, Jackisch Christian, Nekljudova Valentina, Burchardi Nicole, Loibl Sibylle, Simon Eike, Stickeler Elmar, Potenberg Jochem, Conrad Bettina, Reimer Toralf, Decker Thomas, Eidtmann Holger, Eiermann Wolfgang, Hackmann John, Möbus Volker, Marme Frederik, German Breast Group Investigators
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
Loibl S, Mehta K, Nekljudova V, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Kümmel S, Paepke S, Untch M, Lederer B, Jackisch C, von Minckwitz G. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat 2015; 152:377-87.
25.06.2015Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
25.06.2015Breast Cancer Res Treat 2015; 152:377-87
Loibl Sibylle, Mehta Keyur, Nekljudova Valentina, Blohmer Jens-Uwe, Costa Serban Dan, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Hanusch Claus, Hilfrich Jörn, Huober Jens, Schneeweiss Andreas, Kümmel Sherko, Paepke Stefan, Untch Michael, Lederer Bianca, Jackisch Christian, von Minckwitz Gunter
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
Hanusch C, Burchardi N, Engels K, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hilfrich J, Huober J, Jackisch C, Kümmel S, Paepke S, Untch M, Loibl S, Schneeweiss A, von Minckwitz G. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). Clin Cancer Res 2015; 21:2924-31.
30.03.2015Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
30.03.2015Clin Cancer Res 2015; 21:2924-31
Hanusch Claus, Burchardi Nicole, Engels Knut, Blohmer Jens Uwe, Costa Serban, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Hilfrich Jörn, Huober Jens, Jackisch Christian, Kümmel Sherko, Paepke Stefan, Untch Michael, Loibl Sibylle, Schneeweiss Andreas, von Minckwitz Gunter
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Fontanella C, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Huober J, Hilfrich J, Hanusch C, Lederer B, Gade S, Vanoppen M, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Loibl S. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015; 150:127-39.
13.02.2015Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
13.02.2015Breast Cancer Res Treat 2015; 150:127-39
Fontanella Caterina, Schneeweiss Andreas, Paepke Stefan, Jackisch Christian, Mehta Keyur, Nekljudova Valentina, Untch Michael, Neven Patrick, von Minckwitz Gunter, Huober Jens, Hilfrich Jörn, Hanusch Claus, Lederer Bianca, Gade Stephan, Vanoppen Mieke, Blohmer Jens Uwe, Costa Serban Dan, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Loibl Sibylle
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study
Klauschen F, Denkert C, Dietel M, Lederer B, Mehta K, Erbstößer E, Rüdiger T, Huober J, Blohmer J, Gerber B, Loibl S, Schmitt W, Wienert S, von Minckwitz G. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. Clin Cancer Res 2014; 21:3651-7.
11.12.2014Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study
11.12.2014Clin Cancer Res 2014; 21:3651-7
Klauschen Frederick, Denkert Carsten, Dietel Manfred, Lederer Bianca, Mehta Keyur, Erbstößer Erhard, Rüdiger Thomas, Huober Jens, Blohmer Jens-Uwe, Gerber Bernd, Loibl Sibylle, Schmitt Wolfgang D, Wienert Stephan, von Minckwitz Gunter
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
Loibl S, Fasching P, Andre F, Lindner J, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Pfitzner B, Huober J, Heinrichs C, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm D, Sinn P, Khandan F, Eidtmann H, Dohnal K, Denkert C. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32:3212-20.
08.09.2014PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
08.09.2014J Clin Oncol 2014; 32:3212-20
Loibl Sibylle, Fasching Peter A, Andre Fabrice, Lindner Judith L, Sotiriou Christos, Dykgers August, Guo Sanxing, Gade Stephan, Nekljudova Valentina, Loi Sherene, Untch Michael, Pfitzner Berit, Huober Jens, Heinrichs Clemens, von Minckwitz Gunter, Schneeweiss Andreas, Paepke Stefan, Lehmann Annika, Rezai Mahdi, Zahm Dirk M, Sinn Peter, Khandan Fariba, Eidtmann Holger, Dohnal Karel, Denkert Carsten
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
von Minckwitz G, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching P, Sinn B, Engels K, Mehta K, Nekljudova V, Klare P, Eidtmann H, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer J, Jackisch C, Paepke S, Gerber B, Zahm D, Kümmel S, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15:747-56.
30.04.2014Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
30.04.2014Lancet Oncol 2014; 15:747-56
von Minckwitz Gunter, Huober Jens, Costa Serban, Tesch Hans, Hanusch Claus, Hilfrich Jörn, Khandan Fariba, Fasching Peter A, Sinn Bruno V, Engels Knut, Mehta Keyur, Nekljudova Valentina, Klare Peter, Eidtmann Holger, Schneeweiss Andreas, Loibl Sibylle, Salat Christoph, Denkert Carsten, Rezai Mahdi, Blohmer Jens U, Jackisch Christian, Paepke Stefan, Gerber Bernd, Zahm Dirk M, Kümmel Sherko, Untch Michael
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
Loibl S, Denkert C, Hilfrich J, Konecny G, Fett W, Stickeler E, Harbeck N, Mehta K, Nekljudova V, von Minckwitz G, Huober J, Kümmel S, Volz C, Mau C, Blohmer J, Costa S, Eidtmann H, Fasching P, Gerber B, Hanusch C, Jackisch C, Untch M. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat 2014; 144:153-62.
07.02.2014Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
07.02.2014Breast Cancer Res Treat 2014; 144:153-62
Loibl Sibylle, Denkert Carsten, Hilfrich Jörn, Konecny Gottfried E, Fett Werner, Stickeler Elmar, Harbeck Nadia, Mehta Keyur M, Nekljudova Valentina, von Minckwitz Gunter, Huober Jens, Kümmel Sherko, Volz Cristina, Mau Christine, Blohmer Jens-Uwe, Costa Serban D, Eidtmann Holger, Fasching Peter A, Gerber Bernd, Hanusch Claus, Jackisch Christian, Untch Michael
Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
Hilvo M, Orešič M, Denkert C, von Minckwitz G, Huober J, Untch M, Sysi-Aho M, Seppänen-Laakso T, Nekljudova V, Hyötyläinen T, Gade S, Loibl S. Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 2013; 134:1725-33.
08.10.2013Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
08.10.2013Int J Cancer 2013; 134:1725-33
Hilvo Mika, Orešič Matej, Denkert Carsten, von Minckwitz Gunter, Huober Jens, Untch Michael, Sysi-Aho Marko, Seppänen-Laakso Tuulikki, Nekljudova Valentina, Hyötyläinen Tuulia, Gade Stephan, Loibl Sibylle
Response-guided neoadjuvant chemotherapy for breast cancer
von Minckwitz G, Mehta K, Zahm D, Untch M, Schneeweiss A, Paepke S, Kümmel S, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eiermann W, Eidtmann H, Denkert C, Costa S, Blohmer J, Loibl S. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31:3623-30.
03.09.2013Response-guided neoadjuvant chemotherapy for breast cancer
03.09.2013J Clin Oncol 2013; 31:3623-30
von Minckwitz Gunter, Mehta Keyur, Zahm Dirk Michael, Untch Michael, Schneeweiss Andreas, Paepke Stefan, Kümmel Sherko, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Hanusch Claus, Gerber Bernd, Eiermann Wolfgang, Eidtmann Holger, Denkert Carsten, Costa Serban Dan, Blohmer Jens Uwe, Loibl Sibylle
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
von Minckwitz G, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching P, Karn T, Müller V, Jackisch C, Huober J, Hilfrich J, Tesch H, Schmitt W, Loibl S, Müller B, Blohmer J, Sinn B, Eidtmann H, Eiermann W, Gerber B, Denkert C. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013; 19:4521-31.
27.06.2013Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
27.06.2013Clin Cancer Res 2013; 19:4521-31
von Minckwitz Gunter, Fehm Tanja, Barinoff Jana, Rüdiger Thomas, Erbstoesser Erhard, Fasching Peter A, Karn Thomas, Müller Volkmar, Jackisch Christian, Huober Jens, Hilfrich Jörn, Tesch Hans, Schmitt Wolfgang D, Loibl Sibylle, Müller Berit M, Blohmer Jens U, Sinn Bruno V, Eidtmann Holger, Eiermann Wolfgang, Gerber Bernd, Denkert Carsten
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Denkert C, von Minckwitz G, Tesch H, Hansmann M, Reinisch M, Engels K, Sinn B, Fasching P, Mehta K, Solbach C, Brase J, Darb-Esfahani S, Kronenwett R, Prinzler J, Loibl S, Huober J, Untch M. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013; 15:R11.
07.02.2013HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
07.02.2013Breast Cancer Res 2013; 15:R11
Denkert Carsten, von Minckwitz Gunter, Tesch Hans, Hansmann Martin-Leo, Reinisch Mattea, Engels Knut, Sinn Bruno V, Fasching Peter A, Mehta Keyur, Solbach Christine, Brase Jan C, Darb-Esfahani Silvia, Kronenwett Ralf, Prinzler Judith, Loibl Sibylle, Huober Jens, Untch Michael
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-804.
16.04.2012Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
16.04.2012J Clin Oncol 2012; 30:1796-804
von Minckwitz Gunter, Mehta Keyur, Nekljudova Valentina, Denkert Carsten, Konecny Gottfried E, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Eiermann Wolfgang, Gerber Bernd, Fasching Peter A, Eidtmann Holger, Costa Serban D, Blohmer Jens-Uwe, Untch Michael, Loibl Sibylle
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
26.01.2012Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
26.01.2012N Engl J Med 2012; 366:299-309
von Minckwitz Gunter, Blohmer Jens-Uwe, Huober Jens, Hauschild Maik, Fehm Tanja, Müller Berit Maria, Denkert Carsten, Loibl Sibylle, Nekljudova Valentina, Untch Michael, German Breast Group, Kunz Georg, Jackisch Christian, Gerber Bernd, Eidtmann Holger, Rezai Mahdi, Fasching Peter A, Tesch Hans, Eggemann Holm, Schrader Iris, Kittel Kornelia, Hanusch Claus, Kreienberg Rolf, Solbach Christine, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
von Minckwitz G, Untch M, Diebold K, Tiemann K, Hoffmann G, Henschen S, Schrader I, Hanusch C, Clemens M, Just M, Dietrich K, Eidtmann H, Holms F, Solbach C, Tesch H, Huober J, Loibl S, Darb-Esfahani S, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011
12.06.2011Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
12.06.2011Breast Cancer Res Treat 2011
von Minckwitz Gunter, Untch Michael, Diebold Kurt, Tiemann Katharina, Hoffmann Gerald, Henschen Stephan, Schrader Iris, Hanusch Claus, Clemens Michael R, Just Marianne, Dietrich Klaus, Eidtmann Holger, Holms Frank, Solbach Christine, Tesch Hans, Huober Jens, Loibl Sibylle, Darb-Esfahani Silvia, Denkert Carsten
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
von Minckwitz G, Zahm D, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, du Bois A, Blohmer J, Müller B, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29:2150-7.
25.04.2011Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
25.04.2011J Clin Oncol 2011; 29:2150-7
von Minckwitz Gunter, Zahm Dirk-Michael, Khandan Fariba, Hoffmann Gerald, Gerber Bernd, Eidtmann Holger, Fend Falko, Dietel Manfred, Mehta Keyur, du Bois Andreas, Blohmer Jens Uwe, Müller Berit Maria, Loibl Sibylle, Budczies Jan, Hanusch Claus, Darb-Esfahani Silvia, Hilfrich Jörn, Weiss Erich, Huober Jens, Denkert Carsten
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Huober J, Mehta K, Darb-Esfahani S, Högel B, Thomssen C, Hauschild M, Khandan F, Belau A, Zahm D, Weiss E, Tesch H, Denkert C, von Minckwitz G, Loibl S. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124:133-40.
10.08.2010Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
10.08.2010Breast Cancer Res Treat 2010; 124:133-40
Huober Jens, Mehta Keyur, Darb-Esfahani Silvia, Högel Bernhard, Thomssen Christoph, Hauschild Maik, Khandan Fariba, Belau Antje, Zahm Dirk Michael, Weiss Erich, Tesch Hans, Denkert Carsten, von Minckwitz Gunter, Loibl Sibylle